A clinical guide to using intravenous proton-pump inhibitors in reflux and peptic ulcers

Therapeutic Advances in Gastroenterology

Volumn 3, Issue 1, 2010, Pages 11-22

  Pang, Sandy H ^a   Graham, David Y ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Acid secretion; Bleeding ulcer; Gastroesophageal reflux disease; Gastrointestinal hemorrhage; H2 receptor antagonist; Peptic ulcer; Proton pump inhibitor (PPI); Stress ulcer; Zollinger Ellison syndrome

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

BACTERIAL PERITONITIS; COST EFFECTIVENESS ANALYSIS; DRUG ADMINISTRATION; DRUG COST; DRUG HALF LIFE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL REFLUX; HOSPITAL INFECTION; HUMAN; LIVER CIRRHOSIS; PEPTIC ULCER; PEPTIC ULCER BLEEDING; PNEUMONIA; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; ZOLLINGER ELLISON SYNDROME;

EID: 77953446411     PISSN: 1756283X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756283X09352095     Document Type: Review

References (79)

1. Afif, W., Alsulaiman, R., Martel, M. and Barkun, A.N. ( 2007) Predictors of inappropriate utilization of intravenous proton pump inhibitors. Aliment Pharmacol Ther 25: 609-615.
2. Ali, T. and Harty, R.F. (2009) Stress-induced ulcer bleeding in critically ill patients. Gastroenterol Clin North Am 38: 245-265.
3. Andriulli, A., Loperfido, S., Focareta, R., Leo, P., Fornari, F., Garripoli, A. et al. (2008) High- versus low-dose proton pump inhibitors after endoscopic hemostasis in patients with peptic ulcer bleeding: a multicentre, randomized study. Am J Gastroenterol 103: 3011-3018.
4. Bajaj, J.S., Dua, K.S., Hanson, K. and Presberg, K. ( 2007) Prospective, randomized trial comparing effect of oral versus intravenous pantoprazole on rebleeding after nonvariceal upper gastrointestinal bleeding: A pilot study. Dig Dis Sci 52: 2190-2194.
5. Bajaj, J.S., Zadvornova, Y., Heuman, D.M., Hafeezullah, M., Hoffmann, R.G., Sanyal, A.J. et al. (2009) Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol 104: 1130-1134.
6. Barkun, A., Bardou, M., Marshall, J.K. and for the Nonvariceal Upper GI Bleeding Consensus Conference Group (2003) Consensus recommendations for managing patients with non-variceal upper gastrointestinal bleeding. Ann Intern Med 139: 843-857.
7. Barkun, A.N., Cockeram, A.W., Ploure, V. and Fedorak, R.N. ( 1999) Review article: acid suppression in non-variceal acute upper gastrointestinal bleeding. Aliment Pharmacol Ther 13: 1565-1584.
8. Barkun, A.N., Herba, K., Adam, V., Kennedy, W., Fallone, C.A. and Bardou, M. ( 2004a) High-dose intravenous proton pump inhibition following endoscopic therapy in the acute management of patients with bleeding peptic ulcers in the USA and Canada: a cost-effective analysis. Aliment Pharmacol Ther 19: 591-600.
9. Barkun, A.N., Herba, K., Adam, V., Kennedy, W., Fallone, C.A. and Bardou, M. ( 2004b) The cost-effectiveness of high-dose oral pump inhibition after endoscopy in the acute treatment of peptic ulcer bleeding. Aliment Pharmacol Ther 20: 195-202.
10. Blatchford, O., Murray, W.R. and Blatchford, M. ( 2000) A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. Lancet 356: 1318-1321.
11. British Society of Gastroenterology Endoscopy Committee ( 2002) Non-variceal upper gastrointestinal hemorrhage: Guidelines. Gut 51(Suppl. 4): iv1-iv6
12. Cai, Q., Barrie, M., Olejeme, H. and Rosenberg, M.D. ( 2008) A pilot study of efficacy and safety of continuous intravenous infusion of pantoprazole in the treatment of severe erosive esophagitis. Dig Dis Sci 53: 1500-1505.
13. Cook, D., Guyatt, G., Marshall, J., Leasa, D., Fuller, H., Hall, R. et al. (1998) A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med 338: 791-797.
14. Cook, D.J., Fuller, H.D., Guyatt, G.H., Marshall, J.C., Leasa, D., Hall, R. et al. (1994) Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med 330: 377-381.
15. Cook, D.J., Witt, L.G., Cook, R.J. and Guyatt, G.H. ( 1991) Stress ulcer prophylaxis in the critically ill: a meta-analysis. Am J Med 91: 519-527.
16. Czaja, A.J., McAlhany, J.C. and Pruitt Jr, B.A. ( 1974) Acute gastroduodenal disease after thermal injury. An endoscopic evaluation of incidence and natural history. N Engl J Med 291: 925-929.
17. Daneshmend, T.K., Hawkey, C.J., Langman, M.J., Logan, R.F., Long, R.G. and Walt, R.P. ( 1992) Omeprazole versus placebo for acute upper gastrointestinal bleeding: randomized double blind controlled trial. BMJ 304: 143-147.
18. Dekkers, C.P., Beker, J.A., Thjodleifsson, B., Gabryelewicz, A., Bell, N.E. and Humphries, T.J. ( 1999) Double-blind comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. Aliment Pharmacol Ther 13: 49-57.
19. Ellison, R.T., Perez-Perez, G., Welsh, C.H., Blaser, M.J., Riester, K.A., Cross, A.S. et al. (1996) Risk factors for upper gastrointestinal bleeding in intensive care unit patients: role of helicobacter pylori. Federal Hyperimmune Imunoglobulin Therapy Study Group. Crit Care Med 24: 1974-1981.
20. Enns, R.A., Gagnon, Y.M., Rioux, K.P. and Levy, A.R. ( 2003) Cost-effectiveness in Canada of intravenous proton pump inhibitors for all patients presenting with acute upper gastrointestinal bleeding. Aliment Pharmacol Ther 17: 225-233.
21. Erstad, B.L. ( 2004) Cost-effectiveness of proton pump inhibitor therapy for acute peptic ulcer-related bleeding. Crit Care Med 32: 1277-1283.
22. Furuta, T., Ohashi, K., Kamata, T., Takashima, M., Kosuge, K., Kawasaki, T. et al. (1998) Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 129: 1027-1230.
23. Furuta, T., Shirai, N., Sugimoto, M., Nakamura, A., Hishida, A. and Ishizaki, T. ( 2005) Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 20: 153-167.
24. Gardner, T.B. and Robertson, D.J. ( 2006) Stress ulcer prophylaxis in non-critically ill patients: less may be more. Am J Gastroenterol 101: 2206-2208.
25. Guda, N.M., Noonan, M., Kreiner, M.J., Partington, S. and Vakil, N. ( 2004) Use of intravenous proton pump inhibitors in community practice: an explanation for the shortage? Am J Gastroenterol 99: 1233-1237.
26. Hartmann, M., Ehrlich, A., Fuder, H., Luhmann, R., Emeklibas, S., Timmer, W. et al. (1998) Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole. Aliment Pharmacol Ther 12: 1027-1032.
27. Hasselgren, G., Lind, T., Lundell, L., Aadland, E., Efskind, P., Falk, A. et al. (1997) Continuous intravenous infusion of omeprazole in elderly patients with peptic ulcer bleeding. Results of a placebo-controlled multicenter study. Scand J Gastroenterol 32: 328-333.
28. Herzig, S.J., Howell, M.D., Ngo, L.H. and Marcantonio, E.R. (2009) Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 301: 2120-2128.
29. Javid, G., Zargar, S.A., U-Saif, R., Khan, B.A., Yatoo, G.N., Shah, A.H. et al. (2009) Comparison of p.o. and i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer. J Gastroenterol Hepatol 24: 1236-1243.
30. Jensen, D.M., Pace, S.C., Soffer, E., Comer, G.M. and 315 Study Group (2006) Continuous infusion of pantoprazole versus ranitidine for prevention of ulcer rebleeding; a US multicenter, randomized, double-blind study. Am J Gastroenterol 101: 1991-1999.
31. Julapalli, V.R. and Graham, D.Y. ( 2005) Appropriate use of intravenous proton pump inhibitors in the management of bleeding peptic ulcer. Dig Dis Sci 50: 1185-1193.
32. Kahi, C.J., Jensen, D.M., Sung, J.J., Bleau, B.L., Jung, H.K., Eckert, G. et al. (2005) Endoscopic therapy versus medical therapy for bleeding peptic ulcer with adherent clot: a meta-analysis. Gastroenterology 129: 855-862.
33. Kaplan, G.G., Bates, D., McDonald, D., Panaccione, R. and Romagnuolo, J. ( 2005) Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions. Clin Gastroenterol Hepatol 3: 1207-1214.
34. Keating, G.M. and Figgitt, D.P. ( 2004) Intravenous esomeprazole. Drugs 64: 875-82; discussion 883.
35. Kovacs, T.O., Lee, C.Q., Chiu, Y.L., Pilmer, B.L. and Metz, D.C. ( 2004) Intravenous and oral lansoprazole are equivalent in suppressing stimulated acid output in patient volunteers with erosive oesophagitis. Aliment Pharmacol Ther 20: 883-889.
36. Laine, L. and Peterson, W. ( 1994) Bleeding peptic ulcer. N Engl J Med 331: 717-727.
37. Laine, L., Shah, A. and Bemanian, S. ( 2008) Intragastric pH with oral vs intravenous bolus plus infusion pump inhibitor therapy in patients with bleeding ulcers. Gastroenterology 134: 1836-1841.
38. Laine, L., Stein, C. and Sharma, V. ( 1996) A prospective outcome study of patients with clot in an ulcer and the effect of irrigation. Gastrointest Endosc 43: 107-110.
39. Lau, J.Y., Leung, W.K., Wu, J.C., Chan, F.K., Wong, V.W., Chiu, P.W. et al. (2007) Omeprazole before endoscopy in patients with gastrointestinal bleeding. N Engl J Med 356: 1631-1640.
40. Lau, J.Y., Sung, J.J., Lee, K.K., Yung, M.Y., Wong, S.K., Wu, J.C. et al. (2000) Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med 343: 310-316.
41. Leontiadis, I.G., Sharma, V.K. and Howden, C.W. ( 2006) Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev 1: CD002094.
42. Lew, E.A., Pisegna, J.R., Starr, J.A., Soffer, E.F., Forsmark, C. and Modlin, I.M. ( 2000) Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology 118: 696-704.
43. Lin, H.J., Lo, W.C., Chen, Y.C. and Perng, C.L. ( 2006) Role of intravenous omeprazole in patients with high-risk of peptic ulcer bleeding after successful endoscopic epinephrine injection: A prospective randomized comparative trial. Am J Gastroenterol 101: 500-505.
44. Lin, M.S., Sun, P. and Yu, H.Y. ( 1998) Evaluation of buffering capacity and acid neutralizing-pH time profile of antacids. J Formos Med Assoc 97: 704-710.
45. Maton, P.N. ( 1996) Zollinger-Ellison syndrome. Recognition and management of acid hypersecretion. Drugs 52: 33-44.
46. Merki, H.S. and Wilder-Smith, C.H. ( 1994) Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing? Gastroenterology 106: 60-64.
47. Messori, A., Trippoli, S., Vaiani, M., Gorini, M. and Corrado, A. ( 2000) Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomized controlled trials. BMJ 321: 1103-1106.
48. Metz, D.C., Amer, F., Hunt, B., Vakily, M., Kukulka, M.J. and Samra, N. ( 2006) Lansoprazole regimens that sustain intragastric pH >6: an evaluation of intermittent oral and continuous intravenous lansoprazole or ranitidine. Aliment Pharmacol Ther 23: 985-995.
49. Metz, D.C., Forsmark, C., Lew, E.A., Starr, J.A., Soffer, E.F., Bochenek, W. et al. (2001) Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Am J Gastroenterol 96: 3274-3280.
50. Metz, D.C., Pratha, V., Martin, P., Paul, J., Maton, P.N., Lew, E. et al. (2000) Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease. Am J Gastroenterol 95: 626-633.
51. Metz, D.C., Soffer, E., Forsmark, C.E., Cryer, B., Chey, W., Bochenek, W. et al. (2003) Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion. Am J Gastroenterol 98: 310-317.
52. Miano, T.A., Reichert, M.G., Houle, T.T., MacGregor, D.A., Kincaid, E.H. and Bowton, D.L. (2009) Nosocomial pneumonia risk and stress ulcer prophylaxis: a comparison of pantoprazole vs ranitidine in cardiothoracic surgery patients. Chest 136: 440-447.
53. Mutlu, G.M., Mutlu, E.A. and Factor, P. ( 2001) GI complications in patients receiving mechanical ventilation. Chest 119: 1222-1241.
54. Ostro, M.J., Russell, J.A., Soldin, S.J., Mahon, W.A. and Jeejeebhoy, K.N. ( 1985) Control of gastric pH with cimetidine: boluses versus primed infusions. Gastroenterology 89: 532-537.
55. Package insert. Nexium IV (esomeprazole). Wilmington, DE: Astra-Zeneca PLC. Available at: http://www.1.astrazeneca-us.com/pi/nexium_iv.pdf, accessed 5 July 2009.
56. Package insert. Prevacid IV (lansoprazole). Lake Forest, IL: TAP Pharmaceutical Products. http://pitap.abbott.com/prevacidiv.pdf?noCache=,accessed5July2009.
57. Package insert. Protonix IV (pantoprazole). Madison, WI : Wyeth Pharmaceuticals. http://www.wyeth.com/content/showlabeling.asp?id=469, accessed 5 July 2009.
58. Peura, D.A. and Johnson, L.F. ( 1985) Cimetidine for prevention and treatment of gastroduodenal mucosal lesions in patients in an intensive care unit. Ann Intern Med 103: 173-177.
59. Quenot, J.P., Thiery, N. and Barbar, S. (2009) When should stress ulcer prophylaxis be used in the ICU? Curr Opin Crit Care 15: 139-143.
60. Richardson, P., Hawkey, C.J. and Stack, W.A. ( 1998) Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs 56: 307-335.
61. Richter, J.E. and Bochenek, W. ( 2000) Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group. Am J Gastroenterol 95: 3071-3080.
62. Rockall, T.A., Logan, R.F., Devlin, H.B. and Northfield, T.C. ( 1996) Risk assessment after acute upper gastrointestinal haemorrhage. Gut 38: 316-321.
63. Saeed, Z.A., Ramirez, F.C., Hepps, K.S., Cole, R.A. and Graham, D.Y. ( 1995) Prospective validation of the Baylor bleeding score for predicting the likelihood of rebleeding after endoscopic hemostasis of peptic ulcers. Gastrointest Endosc 41: 561-565.
64. Sagar, M., Tybring, G., Dahl, M.L., Bertilsson, L. and Seensalu, R. ( 2000) Effects of omperazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism. Gastroenterology 119: 670-676.
65. Schaffalitzky de Muckadell, O.B., Havelund, T., Harling, H., Boesby, S., Snel, P., Vreeburg, E.M. et al. (1997) Effect of omeprazole on the outcome of endoscopically treated bleeding peptic ulcers. Randomized double-blind placebo-controlled multicentre study. Scand J Gastroenterol 32: 320-327.
66. Siepler, J.K., Trudeau, W. and Petty, D.E. ( 1989) Use of continuous infusion of histamine 2-receptor antagonists in critically ill patients. DICP 23: S40-S43
67. Simmons, T.C., Hogan, D.L., Selling, J.A., Maxwell, V. and Isenberg, J.I. ( 1986) The effect of sodium bicarbonate versus aluminium-magnesium hydroxide on postprandial gastric acid in duodenal ulcer patients. J Clin Gastroenterol 8: 146-149.
68. Somberg, L., Morris Jr, J., Fantus, R., Graepel, J., Field, B.G., Lynn, R. et al. (2008) Intermittent intravenous pantoprazole and continuous cimetidine infusion: effect on gastric pH control in critically ill patients at risk of developing stress-related mucosal disease. J Trauma 64: 1202-1210.
69. Stanley, A.J., Ashley, D., Dalton, H.R., Mowat, C., Gaya, D.R., Thompson, E. et al. (2009) Outpatient management of patients with low-risk upper gastrointestinal haemorrhage: multicentre validation and prospective evaluation. Lancet 373: 42-47.
70. Sugimoto, M., Furuta, T., Shirai, N., Ikuma, M., Hishida, A. and Ishizaki, T. ( 2006) Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P 450 2C19 genotype status. Clin Pharmacol Ther 80: 539-548.
71. Sung, J.J.Y., Barkun, A., Kuipers, E.J., Mossner, J., Jensen, D.M., Stuart, R. et al. and for the Peptic Ulcer Bleed Study Group ( 2009) Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. Ann Intern Med 150: 455-464.
72. Sung, J.Y., Chan, F.K., Lau, J.Y., Yung, M.Y., Leung, W.K., Wu, J.C. et al. (2003) The effect of endoscopic therapy in patients receiving omeprazole for bleeding ulcer with nonbleeding visible vessels or adherent clots. A randomized comparison. Ann Intern Med 139: 237-243.
73. Thorens, J., Froehlich, F., Schwizer, W., Saraga, E., Bille, J., Gyr, K. et al. (1996) Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomized double blind study. Gut 39: 54-59.
74. Tsoi, K.K.F., Lau, J.Y.W. and Sung, J.J.Y. ( 2008) Cost-effective analysis of high-dose omeprazole infusion before endoscopy for patients with upper-GI bleeding. Gastrointest Endosc 67: 1056-1063.
75. Udd, M., Miettinen, P., Palmu, A., Heikkinen, M., Janatuinen, E., Pasanen, P. et al. (2001) Regular-dose versus high-dose omeprazole in peptic ulcer bleeding: A prospective randomized double-blind study. Scand J Gastroenterol 36: 1332-1338.
76. Vinayek, R., Hahne, W.F., Euler, A.R., Norton, J.A. and Jensen, R.T. ( 1993) Parenteral control of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Dig Dis Sci 38: 1857-1865.
77. Welage, L.S. ( 2003) Pharmacologic features of proton pump inhibitors and their potential relevance to clinical practice. Gastroenterol Clin North Am 32: S25-S35
78. Wohlt, P.D., Hansen, L.A. and Fish, J.T. ( 2007) Inappropriate continuation of stress ulcer prophylactic therapy after discharge. Ann Pharmacother 41: 1611-1616.
79. Zargar, S.A., Javid, G., Khan, B.A., Yattoo, G.N., Shah, A.H., Gulzar, G.M. et al. (2006) Pantoprazole infusion as adjuvant therapy to endoscopic treatment in patients with peptic ulcer bleeding: prospective randomized controlled trial. J Gastroenterol Hepatol 21: 716-721.